Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1 TCR/IL-15 NK Cells for Relapsed/Refractory Multiple Myeloma
NCT06066359Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2023
- Primary completion
- Aug 2028
- Modality
- TCR-Engineered T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NY-ESO-1 TCR + IL-15 NK in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of dose-limiting toxicities at 28 days and Overall response rate at 30 days. Started Nov 2023; status: recruiting.
02
Drugs
NY-ESO-1 TCR + IL-15 NK
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06066359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06066359.